ReviewFrontiers in pharmacology2026
Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Butyrate and Butyrate-Producing Bacteria in Cardiovascular-Kidney-Metabolic Syndrome.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global incidence of steatotic liver disease (SLD), driven by metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and the synergistic metabolic dysfunction and alcohol-associated liver disease (MetALD), is fueling a rapid rise in hepatocellular carcinoma (HCC). Regardless of the initial etiology (metabolic, alcoholic, or viral), progression to advanced SLD and HCC is governed by critical shared pathways, which are systemic metabolic dysregulation and inflammation. Identifying a single, targeted pharmacological agent to address this unified pathophysiology is an urgent unmet need. This review addresses the epidemiological links between SLD etiologies and HCC, dissecting their shared metabolic pathophysiology. We evaluate the emerging potential of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a multifunctional therapeutic strategy to target this metabolic hepatic nexus. GLP-1 RAs offer a dual central and peripheral mechanism against SLD progression. Centrally, these GLP-1 RAs modulate appetite and reduce the intake and cravings for high-calorie food and alcohol. Peripherally, these agents induce significant weight loss, enhance insulin sensitivity, and reduce hepatic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.